Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

20.38
+2.6615.01%
Post-market: 20.00-0.3800-1.86%18:20 EDT
Volume:4.69M
Turnover:96.19M
Market Cap:2.61B
PE:-6.22
High:22.67
Open:17.67
Low:17.38
Close:17.72
52wk High:22.67
52wk Low:11.00
Shares:128.19M
Float Shares:60.29M
Volume Ratio:3.75
T/O Rate:7.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2762
EPS(LYR):-4.9816
ROE:-81.72%
ROA:-34.63%
PB:5.73
PE(LYR):-4.09

Loading ...

Generate Biomedicines rises 17.7%

TIPRANKS
·
6 hours ago

Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)

TIPRANKS
·
Aug 17

Generate Biomedicines Shares Fall Following Q2 Financial Results

MT Newswires Live
·
Aug 07

Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate

Benzinga Earnings
·
Aug 06

Generate Biomedicines - Q2 Revenue $6.30 Mln

THOMSON REUTERS
·
Aug 06

Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028

THOMSON REUTERS
·
Aug 06

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 06

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Reuters
·
Aug 06

Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline

Reuters
·
Jun 29

Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)

TIPRANKS
·
Jun 25

Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

TIPRANKS
·
Jun 15

Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x

Simply Wall St.
·
Jun 01

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 29

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Reuters
·
May 27

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

Stock Track
·
May 22

A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

Simply Wall St.
·
May 22

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Dow Jones
·
May 19

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 15

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

TIPRANKS
·
May 14

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

MT Newswires Live
·
May 14